Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.31 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24896143 | 0.80 | YTHDC1 (0.51) | SLC40A1YTHDC1 | |
| SCHEMBL23877220 | 0.79 | ADA (0.40) | — | |
| SCHEMBL12304435 | 0.76 | ADORA2A (0.46) | — | |
| SCHEMBL24896144 | 0.76 | GRM1 (0.33) | SLC40A1GRM5GRM1ROCK2ROCK1 | |
| SCHEMBL24229270 | 0.71 | SLC40A1 (0.36) | SLC40A1GRM1ROCK2ROCK1CDC42BPA | |
| SCHEMBL29340205 | 0.71 | ADORA2A (0.51) | GRM5GRM1 | |
| SCHEMBL8970970 | 0.69 | YTHDC1 (0.66) | YTHDC1 | |
| SCHEMBL15718441 | 0.67 | — | — | |
| SCHEMBL23228232 | 0.67 | TP53 (0.38) | — | |
| SCHEMBL24236911 | 0.67 | YTHDC1 (0.41) | YTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023215805-A1 | ACTIN-BINDING LIM PROTEIN 3 (ABLIM3) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2021237097-A1 | COMPOSITIONS AND METHODS FOR INHIBITING MARC1 GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021072395-A1 | MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021067747-A1 | COMPOSITIONS AND METHODS FOR SILENCING UGT1A1 GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |